| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Tetrahydrocurcumin targets various signaling pathways involved in inflammation, oxidative stress, and cancer. It inhibits the activation of NF-κB and reduces the expression of pro-inflammatory cytokines. It also activates Nrf2, leading to increased expression of antioxidant enzymes. The compound may induce apoptosis in cancer cells and inhibit cell proliferation.
|
|---|---|
| ln Vitro |
Tetrahydrocurcumin (THC) may be better than curcumin because it contains a lot of desirable qualities that curcumin does not. At as low as 1 μM, tetrahydrocurcumin inhibits lipoxygenase. The inhibitory properties of tetrahydrocurcumin against CYP2C9, CYP3A4, CYP1A2, and CYP2D6 was evaluated. Tetrahydrocurcumin inhibits CYP2C9 and, to a lesser extent, CYP3A4 in a dose-dependent manner. The greatest inhibitory effects of tetrahydrocurcumin on CYP2C9 and CYP3A4 occur at 50 to 100 μM. Throughout the concentration range examined, tetrahydrocurcumin did not consistently inhibit CYP1A2 or CYP2D6 in response to dosage. In certain instances, the proportion of inhibition surpasses 100%. assessing how tetrahydrocurcumin affects the viability of cancer cells. Tetrahydrocurcumin was used to treat Sup-T1 cells (T-cell lymphoblastic lymphoma cells), and the MTS test was used to measure the drug's ability to induce growth suppression. The IC50 values for the drug were found to be in the mid-to-high micromolar range [1].
In vitro, tetrahydrocurcumin has been shown to have potent antioxidant activity by scavenging free radicals and reducing oxidative stress. It inhibits the production of pro-inflammatory cytokines and the activation of NF-κB. It also inhibits the growth of various cancer cell lines and induces apoptosis. |
| ln Vivo |
More than one absorption and distribution phase can be seen in serum tetrahydrocurcumin (THC) concentration versus time plots. First, a quick elimination phase was noticed, which was followed by a fast absorption phase with a mean Tmax of 6.8 μg/mL at one hour. Two redistributions with two smaller tetrahydrocurcumin maxima at six and twenty-four hours later, this was followed. The maximum values of both redistribution stages are comparable, at about 1 μg/mL. Urine can discharge up to 8 μg of unaltered tetrahydrocurcumin in a 24-hour period [1].
In vivo, tetrahydrocurcumin has been studied in animal models of inflammation, cancer, and neurodegenerative diseases. It may have anti-inflammatory effects in models of colitis and arthritis. It may also have chemopreventive effects in models of carcinogenesis. Its neuroprotective effects have been studied in models of Alzheimer's disease and Parkinson's disease. |
| Enzyme Assay |
For non-cellular enzyme assays, tetrahydrocurcumin can be tested for antioxidant activity using DPPH, ABTS, or FRAP assays. It can also be tested for inhibition of enzymes such as COX-2, iNOS, and MMPs using standard enzyme activity assays.
|
| Cell Assay |
For in vitro cell-based assays, cancer cell lines and inflammatory cell models are cultured and treated with tetrahydrocurcumin. Cell proliferation, apoptosis, and inflammatory marker expression are assessed using MTT assays, flow cytometry, ELISA, and Western blotting.
|
| Animal Protocol |
For in vivo animal studies, tetrahydrocurcumin can be administered orally or intraperitoneally to animal models of disease. Inflammation models, cancer models, and neurodegenerative disease models can be used.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of tetrahydrocurcumin include solubility in DMSO and ethanol. It is a lipophilic compound and may have moderate oral bioavailability. It is metabolized in the liver and excreted.
|
| Toxicity/Toxicokinetics |
Tetrahydrocurcumin is generally considered safe and has low toxicity. No significant toxicity has been reported in preclinical studies at therapeutic doses.
|
| References | |
| Additional Infomation |
Tetrahydrocurcumin is a β-diketone, a structure in which both double bonds of curcumin are reduced to single bonds. It is a metabolite. It belongs to the β-diketone, polyphenol, and diarylheptane class of compounds. Its function is related to that of curcumin. Tetrahydrocurcumin is a metabolite found or produced in Escherichia coli (K12 strain, MG1655 strain). It has been reported that turmeric contains tetrahydrocurcumin, and relevant data are available for reference.
Tetrahydrocurcumin is a major metabolite of curcumin. It has antioxidant, anti-inflammatory, and anticancer activities. It is considered to be more stable than curcumin and may have better bioavailability. It has been studied for its potential therapeutic applications in various diseases. |
| Molecular Formula |
C₂₁H₂₄O₆
|
|---|---|
| Molecular Weight |
372.41
|
| Exact Mass |
372.157
|
| CAS # |
36062-04-1
|
| Related CAS # |
Tetrahydrocurcumin-d6;1794898-13-7
|
| PubChem CID |
124072
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
564.1±45.0 °C at 760 mmHg
|
| Melting Point |
95-97ºC
|
| Flash Point |
196.2±22.2 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.575
|
| LogP |
2.13
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
27
|
| Complexity |
437
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
LBTVHXHERHESKG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H24O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h5-6,9-12,24-25H,3-4,7-8,13H2,1-2H3
|
| Chemical Name |
1,7-bis(4-hydroxy-3-methoxyphenyl)heptane-3,5-dione
|
| Synonyms |
HZIV 81-2HZIV-81-2HZIV81-2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~268.52 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6852 mL | 13.4261 mL | 26.8521 mL | |
| 5 mM | 0.5370 mL | 2.6852 mL | 5.3704 mL | |
| 10 mM | 0.2685 mL | 1.3426 mL | 2.6852 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA